Facing potential 10–200 % US duties, drug makers are shifting production to Poland for lower costs, EU single-market access, skilled talent, and supply-chain resilience.
Jul 9, 2025
Become a paying subscriber of Default to get access to this post and other subscriber-only content.
Upgrade